Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01144247 : Cellular Immunotherapy Study for Brain Cancer
PhasePhase 1
AgesMin: 18 Years Max: N/A
Eligibility
INCLUSION CRITERIA

To participate in this clinical trial, patients must meet the following eligibility
criteria:

1. Subjects must have a histologically proven diagnosis of malignant glioma or
meningioma and been treated with prior standard radiation and chemotherapy. There
must be evidence of unequivocal progression by MRI.

2. Tumor must be amenable to resection, and surgical resection must be clinically
indicated.

3. Age at least 18 years.

4. Karnofsky performance scale score >60.

5. Adequate hematologic function: a) systemic white blood cell count greater than 2 x
103/mm3, b) platelet count greater than 100,000/mm3, c) hematocrit greater than 25%.

6. Adequate renal function, with creatinine less than two times the upper limit.

7. Adequate hepatic function, with SGOT, alkaline phosphatase, and total bilirubin < 2x
upper limit of normal.

8. Patients must have an expected survival of at least three months.

9. Patients must not have a history of HTLV, HIV, syphilis by RPR, hepatitis B and C.

10. Patients must sign an informed consent.

EXCLUSION CRITERIA

Patients will be excluded from the trial if the patients:

1. have multifocal tumors, bihemispheric tumors, infratentorial tumors, or
non-surgically accessible tumors.

2. have prior tumor resections where the ventricles were extensively breached.

3. are pregnant or breast-feeding women.

4. are females of child-bearing potential unable or unwilling to practice adequate birth
control methods.

5. have contraindications for brain MRI scanning (e.g., intra-ocular metal fragments,
cerebral aneurysm clips, pacemaker).

6. have concurrent malignancy, excluding curatively treated basal or squamous cell
carcinoma of the skin, or carcinoma in situ of the cervix.

7. have concurrent systemic infection.

8. have any clinically significant, uncontrolled medical illness, as determined by the
investigators.

9. are unwilling or unable to comply with procedures required in this protocol.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01144247      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740